Mediwound (NASDAQ:MDWD) had its target price lifted by Oppenheimer from $10.00 to $12.00 in a report issued on Monday. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Mediwound’s Q1 2018 earnings at ($0.13) EPS, Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.15) EPS, Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.60) EPS, FY2019 earnings at ($0.72) EPS and FY2020 earnings at ($0.41) EPS.

Several other equities research analysts have also issued reports on MDWD. Zacks Investment Research lowered shares of Mediwound from a hold rating to a sell rating in a research report on Thursday, January 18th. ValuEngine lowered shares of Mediwound from a sell rating to a strong sell rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $9.25.

How to Become a New Pot Stock Millionaire

Mediwound stock opened at $5.50 on Monday. Mediwound has a 52-week low of $3.56 and a 52-week high of $8.25. The company has a market cap of $146.06, a P/E ratio of -5.61 and a beta of 0.15.

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings results on Monday, March 19th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.08. Mediwound had a negative net margin of 887.38% and a negative return on equity of 234.12%. The firm had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.65 million. research analysts predict that Mediwound will post -0.69 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in MDWD. Renaissance Technologies LLC increased its position in shares of Mediwound by 18.2% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 15,500 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Mediwound by 84.6% in the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 46,366 shares in the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Mediwound in the third quarter worth $1,538,000. Alyeska Investment Group L.P. acquired a new stake in shares of Mediwound in the third quarter worth $2,140,000. Finally, Meitav Dash Investments Ltd. acquired a new stake in shares of Mediwound in the fourth quarter worth $2,184,000. 32.75% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Oppenheimer Increases Mediwound (MDWD) Price Target to $12.00” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/oppenheimer-increases-mediwound-mdwd-price-target-to-12-00/1958487.html.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.